PL376017A1 - Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa - Google Patents

Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa

Info

Publication number
PL376017A1
PL376017A1 PL03376017A PL37601703A PL376017A1 PL 376017 A1 PL376017 A1 PL 376017A1 PL 03376017 A PL03376017 A PL 03376017A PL 37601703 A PL37601703 A PL 37601703A PL 376017 A1 PL376017 A1 PL 376017A1
Authority
PL
Poland
Prior art keywords
kynurenine
islets
diabetes
increasing
treatment
Prior art date
Application number
PL03376017A
Other languages
English (en)
Inventor
Micheline Kergoat
Catherine Kargar
Valerie Autier
De Vacqueur Annick Arbellot
Gerard Moinet
Dominique Marais
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0300107A external-priority patent/FR2849599B1/fr
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL376017A1 publication Critical patent/PL376017A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL03376017A 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa PL376017A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300107A FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR0314263A FR2849598B1 (fr) 2003-01-07 2003-12-04 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans

Publications (1)

Publication Number Publication Date
PL376017A1 true PL376017A1 (pl) 2005-12-12

Family

ID=32598906

Family Applications (2)

Application Number Title Priority Date Filing Date
PL03376017A PL376017A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa
PL378212A PL378212A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL378212A PL378212A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy

Country Status (17)

Country Link
US (2) US7727977B2 (pl)
EP (2) EP1581215B1 (pl)
JP (2) JP2006515594A (pl)
KR (2) KR20050090447A (pl)
AR (2) AR043327A1 (pl)
AT (1) ATE457725T1 (pl)
AU (2) AU2003293937B2 (pl)
BR (2) BR0317950A (pl)
CA (2) CA2512563C (pl)
DE (1) DE60331359D1 (pl)
ES (1) ES2339656T3 (pl)
FR (1) FR2849598B1 (pl)
MX (2) MXPA05007292A (pl)
PL (2) PL376017A1 (pl)
RU (2) RU2005125086A (pl)
TW (2) TW200503676A (pl)
WO (2) WO2004060368A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US8071631B2 (en) * 2006-08-16 2011-12-06 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008022281A1 (en) 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
WO2009071161A1 (en) 2007-12-03 2009-06-11 Merck Patent Gmbh Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders
CN101990431B (zh) 2008-03-12 2014-06-18 迈阿密大学 用于检测和治疗低血糖症的方法和测定法
PL228037B1 (pl) * 2009-03-23 2018-02-28 Marciniak Agnieszka Maria Zastosowanie kwasu kynureninowego w zapobieganiu lub leczeniu chorób trzustki
WO2011082044A1 (en) * 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
EP3915367A1 (en) 2010-08-18 2021-12-01 BioSplice Therapeutics, Inc. Diketones and hydroxyketones as catenin signaling pathway activators
LT2968249T (lt) 2013-02-22 2019-03-12 Samumed, Llc Gama-diketonai, kaip wnt/beta-katenino signalinio kelio aktyvikliai
CN107106549B (zh) 2014-08-20 2020-06-16 萨穆梅德有限公司 用于治疗和预防老化皮肤和皱纹的γ–二酮
HUE054020T2 (hu) * 2014-09-26 2021-08-30 Univ British Columbia Kinurenin és antigénprezentáló sejtek (APC) kombinációja gyógyszerként és módszerek az immunmodulációban történõ használatukra

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181474A (en) * 1978-03-02 1980-01-01 Dunham-Bush, Inc. Vertical axis hermetic rotary helical screw compressor with improved rotary bearings and oil management
EP0570829B1 (de) * 1992-05-18 2001-04-25 CicloMulsion AG Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
DE69423343T2 (de) * 1993-12-22 2000-11-09 Entropy Systems Inc Anlage und verfahren für wärmeübertragung mit luft als arbeitsmedium
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
JP3104966B2 (ja) * 1996-02-19 2000-10-30 日本たばこ産業株式会社 糖尿病治療薬
AU719396B2 (en) * 1996-02-19 2000-05-11 Japan Tobacco Inc. Therapeutic agent for diabetes
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001291579B2 (en) * 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
TW200920357A (en) * 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety

Also Published As

Publication number Publication date
AR043327A1 (es) 2005-07-27
CA2512558A1 (en) 2004-07-22
ES2339656T3 (es) 2010-05-24
MXPA05007292A (es) 2005-09-08
AU2003293937A1 (en) 2004-07-29
JP2006516960A (ja) 2006-07-13
BR0317947A (pt) 2005-11-29
FR2849598A1 (fr) 2004-07-09
TW200503676A (en) 2005-02-01
JP4813800B2 (ja) 2011-11-09
JP2006515594A (ja) 2006-06-01
KR20050090447A (ko) 2005-09-13
TW200418820A (en) 2004-10-01
RU2005125086A (ru) 2006-08-27
US20060052456A1 (en) 2006-03-09
AU2003293937B2 (en) 2009-03-26
AU2003296679A1 (en) 2004-07-29
CA2512563A1 (en) 2004-07-22
PL378212A1 (pl) 2006-03-20
MXPA05007293A (es) 2005-09-08
FR2849598B1 (fr) 2006-09-22
RU2005125085A (ru) 2006-03-20
CA2512563C (en) 2012-06-19
US7727977B2 (en) 2010-06-01
ATE457725T1 (de) 2010-03-15
EP1581216A1 (en) 2005-10-05
EP1581215A1 (en) 2005-10-05
AR042712A1 (es) 2005-06-29
WO2004060369A1 (en) 2004-07-22
EP1581215B1 (en) 2010-02-17
US20060142358A1 (en) 2006-06-29
RU2351329C2 (ru) 2009-04-10
KR20050090443A (ko) 2005-09-13
DE60331359D1 (de) 2010-04-01
BR0317950A (pt) 2005-11-29
WO2004060368A1 (en) 2004-07-22
WO2004060369A8 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
HUS1500035I1 (hu) ATP-kötõ kazetta transzporterek modulátorai
ZA200803701B (en) Modulators of ATP-binding Cassette transporters
EP1804794A4 (en) SPIROPIPERIDINE COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
IL179674A0 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
PT1827441E (pt) Combinações para o tratamento de doenças que envolvem proliferação celular
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
HK1133886A1 (en) Substituted aryl-indole compounds and their kynurenine kynuramine-like metabolites as therapeutic agents
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
NO20090724L (no) Benzylaminer, fremgangsmåte for fremstilling av slike, og anvendelse av dem som betennelseshemmende midler
PL376017A1 (pl) Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa
EP1881756A4 (en) TREATMENT OF DISEASES OF THE MICROVASCULAR SYSTEM WITH ACETYLCHOLINESTERASE INHIBITORS
PL1811866T3 (pl) Zastosowanie związków przeciwutleniających przy uszkodzeniach mięśni
PL1872796T3 (pl) Preparat przezskórny do stosowania zewnętrznego zawierający niesteroidowy lek przeciwzapalny/przeciwbólowy
EP1874755A4 (en) BENZOTHIOPHENE-hydroxamic acid derivatives
SI1597965T1 (sl) Tip brokolija, ki je prilagojen laĹľjemu spravilu pridelka
DK1853609T3 (da) Thienopyridinderivater og anvendelse deraf som hsp90-modulatorer
BRPI0820210A2 (pt) composto, composição farmacêutica, uso de um composto, e, método de tratamento terapêutico de um mamífero.
HK1117737A1 (en) Use of adamantyl methoxydi phenyl propenoic acid for the treatment of acne
WO2007139948A3 (en) Imidazoazepinone compounds
SI2502911T1 (sl) Modulatorji transporterjev ATP vezavne kasete
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
SI1773816T1 (sl) Modulatorji prenaĺ alcev z atp-vezavno kaseto
AP2008004391A0 (en) Pharmaceutical composition suitable for the treatment of malaris within one day

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)